Logo image of RNLX

RENALYTIX AI PLC-ADR (RNLX) Stock Fundamental Analysis

NASDAQ:RNLX - Nasdaq - US75973T1016 - ADR - Currency: USD

0.2071  +0.01 (+5.66%)

After market: 0.13 -0.08 (-37.23%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to RNLX. RNLX was compared to 38 industry peers in the Health Care Technology industry. RNLX may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, RNLX is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year RNLX has reported negative net income.
In the past year RNLX has reported a negative cash flow from operations.
RNLX had negative earnings in each of the past 5 years.
In the past 5 years RNLX always reported negative operating cash flow.
RNLX Yearly Net Income VS EBIT VS OCF VS FCFRNLX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 -10M -20M -30M -40M -50M

1.2 Ratios

With a Return On Assets value of -109.75%, RNLX is not doing good in the industry: 89.19% of the companies in the same industry are doing better.
RNLX has a Return On Equity of -250.48%. This is amonst the worse of the industry: RNLX underperforms 83.78% of its industry peers.
Industry RankSector Rank
ROA -109.75%
ROE -250.48%
ROIC N/A
ROA(3y)-76.55%
ROA(5y)-54.96%
ROE(3y)-138.17%
ROE(5y)-92.72%
ROIC(3y)N/A
ROIC(5y)N/A
RNLX Yearly ROA, ROE, ROICRNLX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 0 200 -200 400 600 800

1.3 Margins

The Gross Margin of RNLX (20.60%) is worse than 86.49% of its industry peers.
The Profit Margin and Operating Margin are not available for RNLX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 20.6%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
RNLX Yearly Profit, Operating, Gross MarginsRNLX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 0 -500 -1K -1.5K -2K

More info and screens

2

2. Health

2.1 Basic Checks

RNLX does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for RNLX has been increased compared to 1 year ago.
The number of shares outstanding for RNLX has been increased compared to 5 years ago.
Compared to 1 year ago, RNLX has a worse debt to assets ratio.
RNLX Yearly Shares OutstandingRNLX Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M
RNLX Yearly Total Debt VS Total AssetsRNLX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M

2.2 Solvency

RNLX has an Altman-Z score of -5.75. This is a bad value and indicates that RNLX is not financially healthy and even has some risk of bankruptcy.
RNLX's Altman-Z score of -5.75 is on the low side compared to the rest of the industry. RNLX is outperformed by 83.78% of its industry peers.
A Debt/Equity ratio of 0.41 indicates that RNLX is not too dependend on debt financing.
The Debt to Equity ratio of RNLX (0.41) is worse than 62.16% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.41
Debt/FCF N/A
Altman-Z -5.75
ROIC/WACCN/A
WACC6.65%
RNLX Yearly LT Debt VS Equity VS FCFRNLX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 0 50M

2.3 Liquidity

RNLX has a Current Ratio of 1.76. This is a normal value and indicates that RNLX is financially healthy and should not expect problems in meeting its short term obligations.
RNLX's Current ratio of 1.76 is in line compared to the rest of the industry. RNLX outperforms 48.65% of its industry peers.
A Quick Ratio of 1.71 indicates that RNLX should not have too much problems paying its short term obligations.
RNLX has a Quick ratio of 1.71. This is comparable to the rest of the industry: RNLX outperforms 48.65% of its industry peers.
Industry RankSector Rank
Current Ratio 1.76
Quick Ratio 1.71
RNLX Yearly Current Assets VS Current LiabilitesRNLX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 20M 40M 60M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 27.23% over the past year.
RNLX shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 14.58%.
EPS 1Y (TTM)27.23%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%74.99%
Revenue 1Y (TTM)14.58%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-68.35%

3.2 Future

Based on estimates for the next years, RNLX will show a very strong growth in Earnings Per Share. The EPS will grow by 21.35% on average per year.
The Revenue is expected to grow by 73.89% on average over the next years. This is a very strong growth
EPS Next Y59.3%
EPS Next 2Y32.95%
EPS Next 3Y21.35%
EPS Next 5YN/A
Revenue Next Year39.85%
Revenue Next 2Y68.91%
Revenue Next 3Y73.89%
Revenue Next 5YN/A

3.3 Evolution

RNLX Yearly Revenue VS EstimatesRNLX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 5M 10M 15M
RNLX Yearly EPS VS EstimatesRNLX Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 -0.2 -0.4 -0.6 -0.8

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

RNLX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for RNLX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RNLX Price Earnings VS Forward Price EarningsRNLX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RNLX Per share dataRNLX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 -0.4 -0.6

4.3 Compensation for Growth

RNLX's earnings are expected to grow with 21.35% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y32.95%
EPS Next 3Y21.35%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for RNLX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

RENALYTIX AI PLC-ADR

NASDAQ:RNLX (10/7/2024, 8:16:27 PM)

After market: 0.13 -0.08 (-37.23%)

0.2071

+0.01 (+5.66%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)05-15 2024-05-15/bmo
Earnings (Next)10-29 2024-10-29/amc
Inst Owners4.26%
Inst Owner Change-95.22%
Ins Owners6.06%
Ins Owner Change265.95%
Market Cap17.18M
Analysts84
Price Target2.67 (1189.23%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)30.74%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)6.97%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 5.05
P/FCF N/A
P/OCF N/A
P/B 0.93
P/tB 2.89
EV/EBITDA N/A
EPS(TTM)-0.61
EYN/A
EPS(NY)-0.23
Fwd EYN/A
FCF(TTM)-0.39
FCFYN/A
OCF(TTM)-0.39
OCFYN/A
SpS0.04
BVpS0.22
TBVpS0.07
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -109.75%
ROE -250.48%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 20.6%
FCFM N/A
ROA(3y)-76.55%
ROA(5y)-54.96%
ROE(3y)-138.17%
ROE(5y)-92.72%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.08
Health
Industry RankSector Rank
Debt/Equity 0.41
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0%
Cap/Sales 0%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.76
Quick Ratio 1.71
Altman-Z -5.75
F-Score2
WACC6.65%
ROIC/WACCN/A
Cap/Depr(3y)34.78%
Cap/Depr(5y)392%
Cap/Sales(3y)44.23%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)27.23%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%74.99%
EPS Next Y59.3%
EPS Next 2Y32.95%
EPS Next 3Y21.35%
EPS Next 5YN/A
Revenue 1Y (TTM)14.58%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-68.35%
Revenue Next Year39.85%
Revenue Next 2Y68.91%
Revenue Next 3Y73.89%
Revenue Next 5YN/A
EBIT growth 1Y26.17%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year40.82%
EBIT Next 3Y19.78%
EBIT Next 5YN/A
FCF growth 1Y29.64%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y28.57%
OCF growth 3YN/A
OCF growth 5YN/A